What does the NextGen GeneCore 161 Somatic Comprehensive Panel at Metropolis Healthcare include?
It covers 161 genes, detects mutations, fusions, CNVs, and evaluates TMB, MSI, and PD-L1 22C3 expression.
How does Metropolis Healthcare perform this comprehensive cancer panel?
Metropolis Healthcare uses high-depth NGS for genomic analysis and validated PD-L1 22C3 immunohistochemistry for biomarker assessment.
Who should consider this test at Metropolis Healthcare?
Patients with solid tumors requiring extensive molecular profiling for targeted or immunotherapy planning should take this test.
Is fasting required for this comprehensive genomic test at Metropolis Healthcare?
No fasting is required; the test uses tumor tissue and/or blood samples based on clinical guidance.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to the breadth of sequencing and immunohistochemistry evaluation.
Can this panel at Metropolis Healthcare help guide immunotherapy decisions?
Yes, TMB, MSI, and PD-L1 22C3 results help clinicians determine suitability for immune checkpoint inhibitor therapies.
How accurate is the sequencing and PD-L1 testing performed by Metropolis Healthcare?
Metropolis Healthcare ensures high analytical accuracy with deep sequencing coverage and rigorously validated PD-L1 22C3 protocols.
Does this test assist in long-term treatment planning at Metropolis Healthcare?
Yes, the comprehensive molecular and immunotherapy insights support personalized therapy planning and ongoing cancer management.